HPV16 L2E7E6融合蛋白疫苗接种部位随机初步研究:用于HPV16阳性宫颈癌治疗后患者
该初步研究将15例完成标准治疗且无疾病证据的HPV16阳性宫颈癌(IB1-IVA期)患者按1:1随机分配至大腿或上臂接受三次100 μg TA-CIN肌内免疫,随访两年评估安全性、免疫应答和复发。接种耐受良好,无复发;大腿接种组TA-CIN特异性抗体滴度倾向于更高,且T细胞克隆扩增显著增加。结论认为大腿或上臂接种均耐受良好,但大腿接种在HPV16阳性宫颈癌治疗后无疾病证据患者中引发更高的CD8 T细胞和抗体应答。
要点
- 15例HPV16阳性宫颈癌治疗后无疾病证据患者随机接受大腿或上臂TA-CIN接种,耐受良好。
- 治疗相关不良事件(n=8)均为1级,主要在注射部位,自行缓解。
- 大腿接种组抗体滴度倾向于更高,T细胞克隆扩增较上臂显著增加。
核心结论
- 大腿或上臂接种TA-CIN均耐受良好,但大腿接种在HPV16阳性宫颈癌治疗后无疾病证据患者中引发更高的CD8 T细胞和抗体应答。
研究设计与样本
- 初步研究(NCT02405221),纳入完成标准治疗一年内且无疾病证据的HPV16阳性宫颈癌(IB1-IVA期)患者,按1:1随机分配至大腿或上臂接受三次100 μg TA-CIN每月肌内免疫,随访两年评估安全性(CTCAEv4.0)、免疫应答和复发。
主要发现
- 共入组15例患者(中位年龄44岁,范围35-83岁);1例在接种一剂后出现非疫苗相关不良事件并退出。
- 治疗相关不良事件(n=8)均为1级,主要在注射部位,自行缓解。
- 未观察到复发。
- 大腿接种组TA-CIN特异性抗体滴度倾向于更高。
- Bulk TCRseq显示大腿接种组较上臂组扩增和新生T细胞克隆显著增加;E6、E7和L2特异性TCR克隆扩增,以L2特异性T细胞应答为主。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Since anti-tumor immunity is enhanced by vaccination of mice adjacent to human papillomavirus type 16 (HPV16+) tumors, we examined whether HPV16 L2E7E6 fusion protein (TA-CIN) vaccination in the thigh of HPV16+ cervical cancer patients would be more immunogenic than their arm. METHODS: HPV16+ cervical cancer (stage IB1-IVA) patients, who had completed standard-of-care treatment within the past year and absent evidence of disease (NED), were enrolled in a pilot study (NCT02405221). Participants were randomized 1:1 to receive three 100 μg TA-CIN monthly intramuscular immunizations either in the arm or thigh and followed for two years for safety (CTCAEv4.0), immune response, and recurrence. RESULTS: Fifteen patients were enrolled (median age 44, range 35-83 years); one patient experienced a non-vaccine-related adverse event after one vaccination and withdrew. Treatment-related adverse events (n = 8) were grade 1, primarily at the injection site, and self-resolved. No recurrence was observed. TA-CIN-specific antibody titers tended to be higher in thigh-vaccinated patients. Bulk TCRseq revealed significant increases in expanded and de novo T cell clones following thigh-vaccination compared with the arm. No correlation with prior treatment modality was observed. E6-, E7-, and L2-specific TCR clones expanded, although L2-specific T cell responses were predominant. One month post-vaccination, scRNAseq revealed significant expansion of MAIT and cytotoxic CD8+ T cells, and both expanded and novel TCR clonotypes were identified in the latter. CONCLUSIONS: Thigh or arm vaccination with TA-CIN was well tolerated, but the former elicited higher CD8 T cell and antibody responses in HPV16+ cervical cancer patients with NED after primary therapy.
引用
- Gaillard S, Alvarez J, Zhang T, et al. A randomized pilot study of HPV16 L2E7E6 fusion protein vaccination site post-treatment for HPV16+ cervical cancer. Gynecol Oncol. 2025. PMID: 40839957. doi:10.1016/j.ygyno.2025.08.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。